Attention-Deficit Hyperactivity Disorder (ADHD) Market Global Sales,Price,Revenue,Gross Margin and Market Share and Forecast to 2026 with top Key players like Takeda Pharmaceutical Company(Japan), Neos Therapeutics, (U.S.), Eli Lilly and Company (U.S.), Pfizer (U.S.)

Press Release

The Global Attention-Deficit Hyperactivity Disorder (ADHD) Market research provides a total cluster of thorough data identified with the worldwide market. The exploration starts from the market division examination alongside the figure of its development designs. The report conveys the diagnostic and measurable information identified with the market to convey an extended stage with business development for associations, item makers and administrations suppliers, and firms. Critical information related with the market is conveyed in a methodological way in this report. The market is bifurcated into different market areas dependent on the thing, applications, topographical locales, and current market designs.

Attention-deficit hyperactivity disorder is defined as a brain disorder in which the patient is hyperactive, impulsive and lacks attention. The cause of this disorder is not yet known but it is expected that a no. of factors like genes, pre-natal brain injuries, exposure of toxins etc. are responsible for ADHD.

Global Attention-Deficit Hyperactivity Disorder Market is expected to rise gradually to an estimated value of USD 17.57 billion by 2026, registering a CAGR of 6.7% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of infants.

FREE | Download PDF Sample report @

Key Market Competitors: Attention-Deficit Hyperactivity Disorder 

Takeda Pharmaceutical Company(Japan), Neos Therapeutics, (U.S.), Eli Lilly and Company (U.S.), Pfizer (U.S.), Alcobra (Israel), Supernus Pharmaceuticals, (U.S.), Noven Pharmaceuticals, (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.), and Curemark, LLC. (U.S.), MonoSol Rx(U.S.), KemPharm, Inc. (U.S.), Neurosigma, Inc. (U.S.), Impax Laboratories, LLC (US), Hisamitsu Pharmaceutical Co.,Inc. (Singapore), Mallinckrodt (UK), UCB S.A. (Belgium), Purdue Pharma L.P. (US), Johnson & Johnson Services (US) and Actavis (U.S.) and few among others.

Market Drivers

  • Increase in focus & advancements in medical field to develop innovative products for ADHD.
  • Increase in awareness about mental illness among people.

Market Restraints

  • Strict government & regulatory guidelines, and increase in the cost of the medication may hamper the market.
  • Limited availability of non-stimulants ADHD drugs will restrain the market.

Table of Contents:

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Global Attention-Deficit Hyperactivity Disorder (ADHD) Market Landscape

Part 04: Global Attention-Deficit Hyperactivity Disorder (ADHD)  Market Sizing

Part 05: Global Attention-Deficit Hyperactivity Disorder (ADHD) Market Segmentation by Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

And More….

To Continue…….!!! | Get Detailed TOC: @

Segmentation: Attention-Deficit Hyperactivity Disorder 

  • By Drug Type
    • Stimulants
    • Non-stimulants
  • By Therapy Type
    • Behavior Therapy
    • Cognitive Behavioral Therapy
    • Interpersonal Psychotherapy
    • Family Therapy
  • By End-User
    • Specialty Clinics
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacy
  • By Demographic type
    • Adult (Aged 18 and above)
    • Children
  • By Geography
    • North America
      • US
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Russia
      • Turkey
      • Belgium
      • Netherlands
      • Switzerland
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • South Korea
      • India
      • Australia
      • Singapore
      • Thailand
      • Malaysia
      • Indonesia
      • Philippines
      • Rest of Asia Pacific
    • Middle East & Africa
      • South Africa
      • Egypt
      • Saudi Arabia
      • United Arab Emirates
      • Israel
      • Rest of Middle East & Africa

Key Developments in the Market:

  • On 20th June 2017, Shire Pharmaceuticals received the US-FDA approval for its product Mydayis, which is Adderall XR (Amphetamine/dextroamphetamine) with the extended delivery. The company has worked on increasing the product life-cycle to generate the revenue. This will help company to grow in the ADHD therapeutic market.
  • On 7th December 2015, Pfizer Inc. has got US-FDA approval for innovative chewable tablets of Methylphenidate under the product name QUILLICHEW ER (extended-release) for patients of 6 and above age group.

Competitive Analysis: Attention-Deficit Hyperactivity Disorder 

Global attention-deficit hyperactivity disorder market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of attention-deficit hyperactivity disorder market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

  • Current and future of global attention-deficit hyperactivity disorder market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)